Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia - Trial NCT05943496
Access comprehensive clinical trial information for NCT05943496 through Pure Global AI's free database. This Phase 1 trial is sponsored by OHSU Knight Cancer Institute and is currently Not yet recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
OHSU Knight Cancer Institute
Timeline & Enrollment
Phase 1
Aug 01, 2023
Jan 01, 2027
Primary Outcome
Incidence of adverse events (AE),Proportion of patients that achieve minimal residual disease (MRD) negativity in peripheral blood
Summary
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and
 obinutuzumab in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL).
 CLL is a type of cancer that develops from a specific white blood cell called B cells or B
 lymphocytes. Tafasitamab and obinutuzumab are monoclonal antibodies that may interfere with
 the ability of cancer cells to grow and spread. Acalabrutinib is in a class of medications
 called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell cancers
 such as CLL at abnormal levels. This may help keep cancer cells from growing and spreading.
 Giving tafasitamab, acalabrutinib, and obinutuzumab may kill more cancer cells in patients
 with newly diagnosed CLL.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05943496
Non-Device Trial